Takeda To Return To Vaccine-Making Business To Meet Local Need
This article was originally published in PharmAsia News
Takeda Pharmaceutical's vaccine business, moribund since 1994, is about to be resumed, company officials say
You may also be interested in...
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.